Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-escalation Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YY2201 in Patients With Advanced Solid Tumors

NCT06976931 is registered in ClinicalTrials.gov with Jiangsu YaYao Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06976931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06976931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-escalation Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YY2201 in Patients With Advanced Solid Tumors
Lead sponsor
Jiangsu YaYao Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 26, 2025
Completion date
October 11, 2027
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors